Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 2
2011 2
2013 2
2014 1
2017 2
2018 1
2019 2
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

11 results
Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Treatment of recurrent ovarian cancer.
Pignata S, C Cecere S, Du Bois A, Harter P, Heitz F. Pignata S, et al. Ann Oncol. 2017 Nov 1;28(suppl_8):viii51-viii56. doi: 10.1093/annonc/mdx441. Ann Oncol. 2017. PMID: 29232464 Free article. Review.
Despite optimal surgery and appropriate first-line chemotherapy, ∼70%-80% of patients with epithelial ovarian cancer will develop disease relapse. ...In patients with partially sensitive relapse (PFI between 6 and 12 months), two o …
Despite optimal surgery and appropriate first-line chemotherapy, ∼70%-80% of patients with epithelial ovarian cancer
PARP Inhibitors in Ovarian Cancer.
Mittica G, Ghisoni E, Giannone G, Genta S, Aglietta M, Sapino A, Valabrega G. Mittica G, et al. Recent Pat Anticancer Drug Discov. 2018;13(4):392-410. doi: 10.2174/1574892813666180305165256. Recent Pat Anticancer Drug Discov. 2018. PMID: 29512470 Free article. Review.
BACKGROUND: Treatment of Epithelial Ovarian Cancer (EOC), historically based on surgery and platinum doublet chemotherapy, is associated with high risk of relapse and poor prognosis for recurrent disease. ...CONCLUSION: PARPis are valuable options in …
BACKGROUND: Treatment of Epithelial Ovarian Cancer (EOC), historically based on surgery and platinum doublet che …
Optimizing treatment of the partially platinum-sensitive ovarian cancer patient.
Colombo N. Colombo N. Future Oncol. 2013 Dec;9(12 Suppl):19-23. doi: 10.2217/fon.13.206. Future Oncol. 2013. PMID: 24195526 Review.
One of the main considerations is the platinum-free interval and, specifically, the optimal treatment for patients who are partially platinum-sensitive (platinum-free interval: 6-12 months). ...In summary, the data suggest t …
One of the main considerations is the platinum-free interval and, specifically, the optimal treatment for patients
Maintenance with Trabectedin in the Treatment of Platinum-Sensitive Recurrent Ovarian Cancer.
Guerra Alía EM, Sempere Ortega C, Cortés Salgado A, Sanchez Martínez C, Galindo Álvarez J, Pérez Miez B. Guerra Alía EM, et al. Case Rep Oncol. 2019 Jun 13;12(2):447-455. doi: 10.1159/000500411. eCollection 2019 May-Aug. Case Rep Oncol. 2019. PMID: 31275136 Free PMC article.
Ovarian cancer is the seventh most common type of cancer and the fifth leading cause of cancer death among women worldwide. The current usual therapeutic approach in this disease includes optimal cytoreductive therapy followed by plati
Ovarian cancer is the seventh most common type of cancer and the fifth leading cause of cancer death among women
Platinum - sensitive relapsed epithelial ovarian cancer: not all the patients benefit from reinduction with carboplatin and paclitaxel.
Milović-Kovačević M, Stamatovic L, Popov I, Radošević-Jelić L, Kezic I. Milović-Kovačević M, et al. Med Sci Monit. 2010 Nov;16(11):CR549-54. Med Sci Monit. 2010. PMID: 20980960
BACKGROUND: It is widely accepted that patients with ovarian cancer relapsing 6 to 12 months after completion of a platinum-based regimen are considered to be partially platinum-sensitive. ...To define the best approach and the …
BACKGROUND: It is widely accepted that patients with ovarian cancer relapsing 6 to 12 months after completion of a p
Emerging treatment strategies in recurrent platinum-sensitive ovarian cancer: focus on trabectedin.
Poveda A, Ray-Coquard I, Romero I, Lopez-Guerrero JA, Colombo N. Poveda A, et al. Cancer Treat Rev. 2014 Apr;40(3):366-75. doi: 10.1016/j.ctrv.2013.08.001. Epub 2013 Aug 8. Cancer Treat Rev. 2014. PMID: 24296108 Free article. Review.
Ovarian cancer (OC) is the leading cause of death from gynecological malignancies. In spite of high response rates to the standard front-line treatment for advanced disease with cytoreductive surgical debulking, followed by platinum/taxane-based chemot
Ovarian cancer (OC) is the leading cause of death from gynecological malignancies. In spite of high response rates to the stan
Effect of the Combination of Trabectedin and Pegylated Liposomal Doxorubicin in a BRCA2 Mutation Carrier with Recurrent Platinum-Sensitive Ovarian Cancer.
Rubio Pérez MJ. Rubio Pérez MJ. Case Rep Oncol. 2017 May 9;10(2):433-437. doi: 10.1159/000475707. eCollection 2017 May-Aug. Case Rep Oncol. 2017. PMID: 28626402 Free PMC article.
INTRODUCTION: The current standard of care for ovarian cancer is optimal cytoreduction with adjuvant chemotherapy based on a platinum/taxane combination. ...CONCLUSIONS: Second-line chemotherapy with a nonplatinum combination - trabectedin plus PLD - w …
INTRODUCTION: The current standard of care for ovarian cancer is optimal cytoreduction with adjuvant chemotherapy based …
TOP2A as marker of response to pegylated lyposomal doxorubicin (PLD) in epithelial ovarian cancers.
Ghisoni E, Maggiorotto F, Borella F, Mittica G, Genta S, Giannone G, Katsaros D, Sciarrillo A, Ferrero A, Sarotto I, Erriquez J, Di Renzo MF, Aglietta M, Valabrega G. Ghisoni E, et al. J Ovarian Res. 2019 Feb 13;12(1):17. doi: 10.1186/s13048-019-0492-6. J Ovarian Res. 2019. PMID: 30760286 Free PMC article.
OBJECTIVE: Relapsed epithelial ovarian cancer (EOC) is frequently treated with pegylated liposomal doxorubicin (PLD). Unfortunately, most patients do not benefit from treatment. ...METHODS: We retrospectively analyzed Formalin Fixed Paraffin Embedded ( …
OBJECTIVE: Relapsed epithelial ovarian cancer (EOC) is frequently treated with pegylated liposomal doxorubicin (PLD). Unfortun …
Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial.
Poveda A, Vergote I, Tjulandin S, Kong B, Roy M, Chan S, Filipczyk-Cisarz E, Hagberg H, Kaye SB, Colombo N, Lebedinsky C, Parekh T, Gómez J, Park YC, Alfaro V, Monk BJ. Poveda A, et al. Ann Oncol. 2011 Jan;22(1):39-48. doi: 10.1093/annonc/mdq352. Epub 2010 Jul 19. Ann Oncol. 2011. PMID: 20643862 Free PMC article. Clinical Trial.
The optimal management of patients with partially platinum-sensitive relapse [6-12 months platinum-free interval (PFI)] is unclear. ...Similar proportions of patients received subsequent therapy in each arm (76% versus 77%), …
The optimal management of patients with partially platinum-sensitive relapse [6-12 months platinum
[Prediction of chemoresistance in epithelial ovarian cancer by clinical factors].
Liang XD, Zeng HX, Zhu HL, Feng YY, Yin LY, Cui H, Wei LH. Liang XD, et al. Zhonghua Yi Xue Za Zhi. 2011 Aug 9;91(29):2030-3. Zhonghua Yi Xue Za Zhi. 2011. PMID: 22093929 Chinese.
METHODS: In references to the 2010 NCCN clinical practice guidelines on ovarian cancer and in accordance with the length of disease-free interval, 244 patients were divided into 3 groups: platinum-resistant, partially sensitive and pla
METHODS: In references to the 2010 NCCN clinical practice guidelines on ovarian cancer and in accordance with the length of di …
11 results
Jump to page
Feedback